Evidence Table 102. KQ 3—Continuous Fasting plasma glucose

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **CVD Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Paolissa199556Crossover | At high risk for CHD | Nifedipine | 88 | Vitamin E | 30 | NRUnit: mmol/L | Mean:5.7SE: 0.6 | NR | NR | N/A | Medium |
| Placebo | 30 | Mean:5.7SE: 0.4 | NR |